Veradermics reported success for its oral hair-loss candidate in a late-stage study, supporting the company’s transition as a public entity. In the trial, men with mild-to-moderate pattern hair loss taking VDPHL01 (once or twice daily) grew about 30 to 33 more hairs per square centimeter over six months versus roughly seven additional hairs in placebo. Veradermics said 79% to 86% of participants reported improvement and 72% to 84% of clinical investigators observed improvements, with the company emphasizing investigator-perceived outcomes in addition to hair count measures. The data set up Veradermics for continued development steps aimed at progressing oral treatment into broader commercialization planning.